Practice Pearls and Closing: Frontline Treatment Intensification as the New Standard in EGFR-Mutated NSCLC

Dr. Gumbleton's primary practice pearl for the management of patients with EGFR-mutated NSCLC in 2026: with very few exceptions, every treatment-naïve patient deserves frontline combination therapy. The data from MARIPOSA and FLAURA2 have fundamentally changed the standard of care, and osimertinib monotherapy is no longer the default for patients who are fit enough to tolerate an intensified regimen. Dose interruptions and modifications are expected and manageable without compromising efficacy; the goal is to get patients on combination therapy and support them through the initial treatment period.

Dr. Fidler reinforces the importance of regimen-specific shared decision-making, emphasizing communication about treatment schedules, anticipated toxicity profiles, and the active ongoing process of toxicity monitoring and management that both regimens require. She highlights that not all patients in FLAURA2 remained on chemotherapy throughout; some transitioned to osimertinib maintenance, confirming that the clinical benefit of frontline intensification is achievable even with regimen modification during the course of treatment.

Dr. Riess closes by acknowledging that although frontline treatment selection for patients with EGFR-mutated NSCLC is now more complex than in the osimertinib monotherapy era, it represents meaningful progress in cancer care. Both amivantamab-lazertinib and osimertinib plus carboplatin-pemetrexed offer superior PFS and OS versus monotherapy, require proactive and specialized toxicity management strategies, and represent the current standard for eligible patients with EGFR-mutated advanced NSCLC.